IngredientsChemical symbol: Cu (from Latin cuprum). Atomic number: 29. Average atomic weight: 63.546. Copper (Cu; atomic number, 29; average atomic weight, 63.546) constitutes approximately 70 ppm of the Earth's crust. Copper is a naturally occurring metal found in soil, water, and rocks, and nutritionally it is an essential trace mineral found in some foods and in supplements.
The electronic configuration of copper ([Ar] 3d¹⁰4s¹) allows it to exist in two oxidation states in biological systems (i.e., Cu²⁺ and Cu¹⁺), which underlies its primary physiological function as a redox catalyst in various metabolic reactions. Due to its high redox potential, excess copper is toxic. The essentiality of copper for humans and animals has been recognized for nearly a century.
Copper in dietary supplements is often in the forms of cupric oxide, cupric sulfate, copper amino acid chelates, and copper gluconate. Copper gluconate, cupric sulfate or oxide, or copper–amino acid chelates are most frequently used in supplements. The relative bioavailability of these different chemical forms of copper has not been extensively investigated.
The richest dietary copper sources include shellfish, seeds and nuts, organ meats, wheat-bran cereals, whole-grain products, and chocolate. Local conditions (e.g., copper content of soil) lead to variations in copper content in various foods. Copper exposure can also occur from tap water (e.g., from copper plumbing).
The use of copper for medicinal purposes dates back to some of the earliest recorded human civilizations. Ancient Egyptians used copper to sterilise water and treat wounds, while the Greeks employed copper compounds to treat ailments.
The Smith Papyrus, an Egyptian medical text written between 2600 and 2200 B.C., records the use of copper to sterilize chest wounds and to sterilize drinking water. Other early reports of copper's medicinal uses are found in the Ebers Papyrus, written around 1500 B.C. The Ebers Papyrus documents medicine practiced in ancient Egypt and in other cultures that flourished many centuries earlier. Copper compounds were recommended for headaches, "trembling of the limbs" (perhaps referring to epilepsy or St. Vitus' Dance), burn wounds, itching, and certain growths in the neck, some of which were probably boils.
Forms of copper used for the treatment of disease ranged from metallic copper splinters and shavings to various naturally occurring copper salts and oxides. A "green pigment" was spoken of, which was probably the mineral malachite, a form of copper carbonate.
In approximately 400 B.C., the Greek Hippocrates, who is known as the father of modern medicine, recommended copper as a treatment for various diseases.
Copper was also employed in ancient India and Persia to treat lung diseases. The tenth-century book Liber Fundamentorum Pharmacologiae describes the use of copper compounds for medicinal purposes in ancient Persia. Powdered malachite was sprinkled on boils; copper acetate and copper oxide were used for diseases of the eye and for the elimination of "yellow bile." Nomadic Mongolian tribes treated and healed ulcers of venereal origin with orally administered copper sulfate.
In ancient India, copper was used for medical equipment including surgical instruments. Even the ancient Aztec civilization used copper for medical purposes, including gargling with copper-infused water to combat sore throats and infections. Similarly, in ancient India and the Far East, copper was used to treat skin conditions, lung diseases, and eye infections.
In Ayurvedic medicine, water stored overnight in copper vessels was believed to balance the body's three doshas — Vata, Pitta, and Kapha.
The first observation of copper's role in the immune system was published in 1867 when it was reported that, during the cholera epidemics in Paris of 1832, 1849 and 1852, copper workers were immune to the disease.
By exploiting the ability of copper to switch between Cu⁺ and Cu²⁺ oxidation states, cuproenzymes drive vitally important metabolic processes including respiration, antioxidant defense, biosynthesis of neuropeptides, and components of connective tissue.
Copper is required for the function of over 30 proteins, including superoxide dismutase, ceruloplasmin, lysyl oxidase, cytochrome c oxidase, tyrosinase, and dopamine-β-hydroxylase.
As cofactors for enzymes, copper ions are required for processes ranging from oxidative phosphorylation, mobilization of iron, connective tissue cross-linking, pigment formation, neuropeptide amidation, catecholamine synthesis, and antioxidant defense. Copper has additional biological roles that may be distinct from serving as a catalytic moiety in cuproenzymes — for example, in the innate immune response, in the modulation of synaptic transmission, and in angiogenesis.
In mammals, copper absorption occurs in the small intestine via enterocyte uptake, followed by its transfer into the blood by the copper transporter ATP7A. The liver plays a critical role in copper metabolism, serving both as the site of copper storage and regulating its distribution to serum and tissues and excretion of excess copper into the bile. Particularly, hepatocytes transport and regulate physiological copper via the specialized transporter ATP7B.
Ceruloplasmin, albumin, and transcuprein, and to a lesser extent certain amino acids, are major copper-transporting constituents in circulating plasma. After hepatic uptake, copper may be stored within hepatocytes, secreted into plasma, or excreted in bile. The biliary route represents the major excretory pathway of copper. Copper retained by hepatocytes is mostly bound to specific metal-binding proteins, primarily metallothionein, or incorporated into several cuproenzymes.
Copper absorption occurs mainly in the upper small intestine. Recent studies in humans using radioisotope tracers suggest that fractional absorption of dietary copper is approximately 50% over a range of intakes (0.7–6 mg/d).
The absorption of copper is strongly influenced by the amount of copper in the diet; bioavailability ranges from 75% of dietary copper when the diet contains only 400 mcg/day to 12% when the diet contains 7.5 mg/day.
Dietary factors, including iron, vitamin C, and zinc, have been reported to exert adverse effects on the bioavailability of copper. The body is typically efficient at stabilizing copper levels (absorption increases if copper intake is low, and vice versa).
The RDA for copper for adults is 900 μg/day. The human body contains approximately 100 mg of Cu, with approximately 75% of the total in skeleton and muscle tissue, whereas the liver, brain, blood, heart, and kidney contain most of the remainder.
Pregnancy and lactation in adults 19+ years requires 1,300 micrograms daily, with a slightly lower amount of 1,000 micrograms daily at younger ages 14–18 years.
The National Academies Institute of Medicine's Tolerable Upper Intake Level (UL) for copper is 10,000 µg/day (10 mg/day) for adults.
Interestingly, copper recommendations for adults in the UK, the European Community, and Australia/New Zealand range from 1.1 to 1.2 mg/d, suggesting that the U.S. and Canadian RDA values for adults may be low.
In adults age 20 and older, average daily intakes of copper from food are 1,400 mcg for men and 1,100 mcg for women. Total intakes from supplements and foods are 1,400 to 1,700 mcg/day for adults age 20 and over.
Copper deficiency is uncommon in humans. Based on studies in animals and humans, the effects of copper deficiency include anemia, hypopigmentation, hypercholesterolemia, connective tissue disorders, osteoporosis, and other bone abnormalities.
Features of copper deficiency include hematologic abnormalities (anemia, neutropenia, and leukopenia) and myeloneuropathy; the latter is a rarer and often unrecognized complication of copper deficiency.
Copper deficiency is associated with a spectrum of aberrations including neurologic manifestations such as sensory ataxia secondary to dorsal column dysfunction, gait difficulties, proprioceptive deficits, and paresthesias; hematologic abnormalities such as hypochromic anemia with neutropenia and leukopenia; as well as myeloneuropathy. The neurologic symptoms may closely resemble the myeloneuropathy indicative of a vitamin B12 deficiency and may be irrevocable if not treated.
Systemic copper deficiency generates cellular iron deficiency, which in humans results in diminished work capacity, reduced intellectual capacity, diminished growth, alterations in bone mineralization, and diminished immune response.
Copper deficiency can impair ceruloplasmin synthesis, which leads to inadequate oxidation of Fe²⁺ to Fe³⁺, disrupts iron mobilization and transport, and results in functional iron deficiency and anemia. The diminished activity of the cupric enzyme mitochondrial cytochrome-c oxidase plays a key role in the transfer of iron to the cytosol for incorporation into heme. Ceruloplasmin ferroxidase is also essential in the loading of transferrin with iron in the liver and is markedly diminished in parallel with copper.
Evidence strength: The mechanistic and clinical evidence linking copper deficiency to anemia and leukopenia is well-established through numerous case reports and cohort studies, particularly in bariatric surgery populations. Although acquired copper deficiency is a rare cause of refractory anemia and leukopenia/neutropenia, it should be considered in the differential diagnosis of a patient with hematologic complications following bariatric surgery, particularly when there is a concomitant neurologic deficit. The evidence for copper supplementation improving anemia in non-deficient populations is not established.
Copper deficiency leads to changes in blood lipid levels, a risk factor for atherosclerotic cardiovascular disease. Animal studies have shown that copper deficiency is associated with cardiac abnormalities, possibly because of the resulting decreases in the activity of several cardiac cuproenzymes.
Copper is a trace mineral that is part of several enzymes and proteins that are essential for adequate use of iron by the body. While frank hypocupremia is rarely seen in the U.S. population, lower copper intake has been implicated with other variables such as heightened cholesterol in some studies as a possible risk factor for cardiovascular disease.
The presence of copper ions in cells serves a dual function; clinical studies have yielded conflicting results regarding the relationship between copper ion levels and the development of cardiovascular disease. Thus, further in-depth research is necessary for future validation.
Evidence strength: Observational studies of the link between copper concentrations and CVD have had mixed results. Evidence from animal models is more consistent, but robust, well-controlled human intervention trials are lacking. Current evidence does not support copper supplementation for CVD prevention in non-deficient individuals.
Copper plays a crucial role in osteoporosis by regulating osteoblast function, inhibiting osteoclast activity, and promoting bone matrix maturation. However, the epidemiological relationship between copper and osteoporosis remains inconclusive.
A 2025 scoping review including 18 studies found that for dietary copper, studies reported that higher intake was associated with improved bone mineral density (BMD). For circulating copper, studies reported that lower levels were associated with higher subsequent risk of osteoporosis and fractures.
However, the protective correlation of dietary copper intake derived from observational studies was not supported by clinical trials. For example, Baker et al. conducted a small-scale trial following 11 participants for merely 8 weeks, focusing on the intermediate outcome osteocalcin. There was no significant difference in serum osteocalcin levels across different groups of low, medium, or high copper intake.
A narrative review that included 10 eligible human studies (five on blood levels, one on daily intake, four on supplementation) found that blood copper levels did not show statistically significant differences in four of the studies analyzed, while only one study showed differences between osteoporotic and healthy women, and only in women between 45 and 59 years of age. The dietary copper intake among women with or without osteoporosis did not show any differences.
Evidence strength: The current evidence is insufficient to delineate a clear dose-response relationship. It remains unclear whether this relationship is linear or U-shaped, and consequently what constitutes an optimal or safe range of copper exposure. These findings underscore the need to develop standardized biomarkers for assessing copper status as well as the importance of conducting long-term interventional studies. Human clinical trial evidence for copper supplementation and bone health remains weak and preliminary.
In recent years, the number of studies about the role of copper metabolism in the pathophysiology of Alzheimer's disease (AD) has been rapidly increasing. A wide range of experimental approaches have been used. Most of these studies have indicated that systemic disarrangements of copper metabolism can be one of the pathologic pathways at the basis of AD, and moreover, preventive and therapeutic strategies based on copper may be developed to slow down or block the disease progression.
There is compelling evidence that in AD, beta amyloid (Aβ) deposition triggers oxidative stress as well as anomalous metal–Aβ protein interaction. Recent studies have shown that metals such as copper, iron, and zinc are key mediating factors in these processes. High concentrations of copper and iron are found within senile plaques and neurofibrillary tangles of AD brains. Both metals can catalyze Fenton's reactions, generating a flux of reactive oxygen species that can potentially damage functional and structural macromolecules.
Studies have found copper deficiency in brain tissue that could be pathogenic in AD, since levels are lowered to values approximating those in Menkes' disease, an X-linked recessive disorder where brain-copper deficiency is the accepted cause of severe brain damage. These studies suggest that interventions aimed at safely and effectively elevating brain copper could provide a new experimental-therapeutic approach.
However, elevating oral copper intake had no effect on cognition in patients with mild AD in a pilot phase 2 clinical trial, although in that study, restoration of brain copper levels was not demonstrated.
Evidence strength: The relationship between copper and AD is highly complex, contested, and not yet resolved. Research has focused on two potential roles: cardiovascular disease and Alzheimer's disease. Some research suggests copper deficiency may be harmful; other research suggests excess free copper may contribute to amyloid pathology. Further studies are necessary to translate findings into clinical practice. Human intervention evidence is very limited.
Lysyl oxidase (LOX) is required for the cross-linking of collagen and elastin fibers, which is essential for the formation of strong and flexible connective tissue. LOX function is critical for bone formation and maintenance of connective tissue in the heart and blood vessels. This mechanistic role is well-established, and copper deficiency demonstrably impairs connective tissue integrity. Evidence that supplementation beyond sufficiency improves these outcomes in healthy individuals has not been established in clinical trials.
Copper has biological roles in the innate immune response. A consequence of the vital enzymatic functions dependent on copper is that copper deficiency has profound clinical outcomes often associated with neurodegeneration. Acquired copper deficiency in humans is clinically associated with impaired neutrophil production (leukopenia), which resolves with repletion. Evidence that supplementation enhances immune function in non-deficient individuals is not well-established in human trials.
Tyrosinase catalyzes the polymerization of tyrosine metabolites to form melanin in melanocytes. Copper deficiency is associated with hypopigmentation of hair and skin due to reduced tyrosinase activity; this is well-documented in deficiency states but is not a basis for supplementation beyond adequacy in healthy individuals.
The Recommended Dietary Allowance (RDA) for adults 19+ years is 900 micrograms daily for men and women. The Tolerable Upper Intake Level (UL) is the maximum daily intake unlikely to cause harmful effects on health. The UL for copper for adults 19+ years is 10,000 micrograms daily.
Most multivitamin dietary supplements on the market include 2 mg of copper, which is the midpoint of the Safe and Adequate Range of Intake recommended by the Food and Nutrition Board.
The Tolerable Upper Intake Level (UL) for adults is 10,000 μg/day (10 mg/day), a value based on protection from liver damage as the critical adverse effect.
In clinical studies on Alzheimer's disease, 30 AD patients received 150 mg once daily of a zinc formulation in which copper monitoring was a critical safety endpoint, with serum ceruloplasmin used as a measure of copper status and hemoglobin levels monitored, as anemia is one of the first manifestations of copper deficiency.
Copper is used clinically mainly to replete copper-deficient individuals. Copper gluconate, cupric sulfate or oxide, or copper–amino acid chelates are most frequently used in supplements.
Copper needs increase in pregnancy (1,000 μg/day) and lactation (1,300 μg/day). Upper tolerable intake levels have been established for copper, varying from 1,000 μg/day at 1–3 years old to 10,000 μg/day in adults.
Copper toxicity is rather rare in humans and animals, because mammals have evolved precise homeostatic control of copper due to the high reactivity of the free metal. Free copper in cells and in the body is extremely low; copper almost always exists bound to proteins.
Excess copper is likely to increase oxidative stress, resulting in tissue/organ damage.
Liver damage in humans is observed almost exclusively in patients with Wilson's disease and children with Indian childhood cirrhosis (ICC) and idiopathic copper toxicosis (ICT). ICC and ICT have been associated with high copper intakes. However, familial relationships and genetic factors are required for the expression of liver toxicity from high levels of copper intake.
Copper toxicity occurs in Wilson disease, which is caused by mutations in the ATP7B gene encoding a hepatic copper transporter that drives excretion of excess copper to the bile. Loss of ATP7B function leads to copper accumulation initially in the liver and subsequently in the brain, thereby causing serious hepatic and neurological abnormalities.
Patients with conditions that increase risk for copper toxicosis, including Wilson disease and biliary cirrhosis and atresia, should avoid taking supplemental copper.
Copper depletion also occurs in the rare genetic disorder Menkes disease. Menkes disease is X-linked, and Wilson disease is an autosomal recessive disorder.
Supplemental copper should be cautiously administered to infants, as toxicity risks are elevated because homeostatic regulation of copper absorption and biliary excretion is not yet fully functional.
Assessing copper status in humans is challenging, since no definitive biomarkers exist for detecting moderate, or subclinical, copper deficiency. The development of more precise and sensitive biomarkers of copper nutritional status is thus a critical area for future research.
Circulating copper may be unexpectedly high during inflammation and may not reflect the actions of copper-dependent enzymes in cells. Furthermore, numerous experiments with animals reveal that plasma copper can be normal or increased even though copper in liver and other organs is low. Low plasma copper indicates physiological impairment.
Although copper is naturally found in water, excessive levels of copper in drinking water are usually caused by leakage from old, corroded household pipes and faucets. There is greater risk if water is stagnant from lack of use or if hot tap water is used (copper more easily dissolves at higher temperatures). In these cases, exposure to excess copper can be decreased by running cold tap water for several minutes before using.
Because dozens of enzymes use copper to perform metabolic processes throughout the body, it is believed that both an excess and deficiency of copper may interrupt these normal processes and a stable level is required for optimal health.
Copper imbalance in humans increases risks of bone demineralization and osteoporosis, fatty liver disease, liver disease mortality, and cardiovascular and neurodegenerative diseases. However, these associations are largely derived from deficiency states, animal studies, and observational data. The RDA for copper (900 μg/day for adults) is sufficient to prevent deficiency, but the lack of clear biomarkers of copper nutritional status in humans makes it difficult to determine the level of copper intake most likely to promote optimum health or prevent chronic disease.
According to an analysis of data from the 2009–2012 National Health and Nutrition Survey (NHANES), 6% to 15% of adults age 19 and older who do not take dietary supplements containing copper have copper intakes below the EAR. In those who do use supplements, rates of adults with intakes below the copper EAR range from 2.2% to 7.2%.
Health conditions that Copper may help support.
Copper is essential for iron absorption, hemoglobin synthesis, and red blood cell formation. Copper deficiency causes anemia (microcytic, normocytic, or macrocytic) and neutropenia. Oral copper supplementation rapidly corrects hematological manifestations; this is well-established in clinical case series and reviews.
Copper is a structural component of Cu/Zn-superoxide dismutase (SOD1), the primary cytoplasmic antioxidant enzyme neutralizing superoxide radicals. Copper supplementation raises erythrocyte SOD1 activity in RCTs. Copper deficiency impairs SOD activity, increasing oxidative stress and inflammatory cytokine production.
Copper is required for lysyl oxidase, the enzyme that crosslinks collagen and elastin in arterial walls, maintaining their structural integrity and elasticity. Epidemiological data from NHANES and the PURE-China cohort link higher dietary copper intake to lower cardiovascular and arterial disease risk. A randomized trial (2 mg/day copper glycinate, 8 weeks) showed copper raised cuproenzyme activities and lowered mean oxidized LDL, though broader cardiovascular markers were not consistently changed.
Copper is an essential cofactor for lysyl oxidase, the enzyme responsible for crosslinking collagen and elastin fibers in the bone matrix. Copper deficiency causes bone abnormalities including osteoporosis-like lesions and impaired collagen crosslinking. The NIH ODS and National Academy of Sciences recognize copper as a micronutrient relevant to bone metabolism and it is consistently included in evidence-based bone supplementation protocols.
Copper is an essential trace mineral and cofactor for lysyl oxidase, the enzyme that catalyzes the cross-linking of collagen and elastin in articular cartilage and connective tissue. Copper deficiency impairs cartilage collagen cross-linking and mechanical integrity. Copper-dependent superoxide dismutase (CuZnSOD) protects chondrocytes from oxidative damage. Copper is included in evidence-based joint supplement formulas supporting cartilage collagen quality.
Copper is a required cofactor for cytochrome c oxidase (Complex IV), the mitochondrial enzyme executing the final step of oxidative phosphorylation to generate ATP. Deficiency causes impaired cellular energy metabolism, metabolic switching to glycolysis, and mitochondrial dysfunction documented in both human genetic diseases and animal models.
Copper is an essential cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin in bone matrix, and for antioxidant enzymes that protect osteoblasts. A 2024 NHANES-based cross-sectional study in 6,965 US children and adolescents aged 8–19 found positive associations between copper intake and total, subtotal, and spinal bone mineral density.
Copper is an essential trace element for iron metabolism, connective tissue formation, antioxidant defense, and neurological function. IOM-established RDAs for children are 340–700 µg/day. NIH ODS-funded label analysis found copper in the 13 core nutrients at or above RDA in most children's MVMs. It is a standard ingredient in all major pediatric multivitamin formulas.
Copper deficiency is associated with elevated LDL, reduced HDL, and impaired cholesterol clearance via ceruloplasmin and HDL metabolism. However, a systematic review and meta-analysis of RCTs found that copper supplementation does not significantly alter total cholesterol, LDL, or HDL in adequately nourished populations.
Copper modulates inflammatory signaling: deficiency elevates pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and activates NF-κB in immune organs. Copper metabolism shifts during inflammation, with serum copper rising as an acute-phase response. Both excess and deficiency of copper can promote dysfunctional inflammatory states.
Copper supports hematopoiesis and iron metabolism essential for blood oxygenation. Ceruloplasmin, a copper-dependent ferroxidase, is required for iron release from stores and incorporation into hemoglobin. Copper deficiency impairs red blood cell production and can cause anemia, directly impairing circulatory oxygen delivery.
Copper homeostasis is deeply implicated in cognitive aging and neurodegeneration. Both deficiency (impairing myelination, neurotransmission, and energy) and excess (promoting amyloid-β aggregation and oxidative neuronal damage) are associated with cognitive decline. Low-normal serum copper correlates with cognitive impairment in older non-demented adults.
Copper is an essential cofactor for lysyl oxidase (LOX), the enzyme that catalyzes post-translational oxidation of lysine and hydroxylysine residues in procollagen and tropoelastin, forming cross-links that give collagen and elastin their tensile strength. Copper deficiency impairs LOX activity, resulting in faulty connective tissue formation. Its role is well-established in peer-reviewed biochemistry and nutrition literature.
Copper is a structural component of cytochrome c oxidase (Complex IV), the terminal electron acceptor in the mitochondrial respiratory chain. Copper deficiency impairs oxidative phosphorylation and reduces cellular ATP production. This link is well-established biochemically and supported by human genetic disease models.
Copper is required for tyrosinase activity (melanin production in hair) and for lysyl oxidase-mediated cross-linking of keratin structural proteins. Deficiency leads to hypopigmentation, hair brittleness, and structural weakness. GHK-Cu peptide has shown hair follicle support in models. Human studies on supplementation for hair growth are limited but deficiency effects are well documented.
Copper's role in SOD1-mediated antioxidant defense, mitochondrial function, connective tissue maintenance, and myelination is relevant to aging trajectories. Dysregulation of copper homeostasis—both excess and deficiency—is associated with age-related neurodegeneration, skin aging, and cardiovascular decline. Serum copper levels in the low-normal range correlate with cognitive decline in older adults.
Copper is essential for normal growth, connective tissue formation, neurological development, hematopoiesis, and immune maturation. Deficiency during development causes structural abnormalities in brain, heart, vessels, bone, skin, and hair. Human Menkes disease demonstrates the catastrophic consequences of severe copper insufficiency in infancy.
Copper deficiency impairs cardiac structure and function through reduced collagen/elastin cross-linking, diminished mitochondrial respiration, and impaired angiogenesis in myocardial tissue. Epidemiological cohort studies link dietary copper intake to myocardial infarction risk. Animal models demonstrate that copper supplementation reverses copper-deficiency-induced cardiac dysfunction.
Copper is a structural and catalytic component of the DAO enzyme, essential for its function. Copper deficiency directly reduces DAO activity, impairing histamine degradation and potentially causing or exacerbating histamine intolerance. Copper is identified as a required cofactor in peer-reviewed HIT literature.
Copper is an obligatory cofactor for tyrosinase, the key enzyme in melanin biosynthesis. Both excess and deficiency of copper can disrupt melanogenesis and pigmentation balance. Copper deficiency causes hypopigmentation, while dysregulated copper-tyrosinase activity is implicated in certain hyperpigmentation conditions.
Copper is essential for iron transport via ceruloplasmin ferroxidase activity. Copper deficiency causes iron-deficiency-like anemia even with adequate iron stores by impairing iron mobilization and transferrin loading. Evidence comes from biochemical, animal, and human clinical data.
Copper was added to the original AREDS formulation (2 mg/day) specifically to counteract the copper-depleting effect of high-dose zinc supplementation, as zinc competitively inhibits copper absorption. Without copper co-supplementation, high zinc intake causes hypocupraemia and associated anemia. Copper is a cofactor for superoxide dismutase (SOD) and is thus part of the standard evidence-based AMD supplement formula. It does not have independent RCT evidence for AMD but is a required component of AREDS therapy.
Copper is a structural and catalytic component of cytochrome c oxidase (Complex IV of the electron transport chain), the primary mitochondrial site of cellular respiration. Copper deficiency causes mitochondrial dysfunction, impaired oxidative phosphorylation, and metabolic reprogramming. This relationship is among the most robustly established biochemical functions of copper.
Copper supports keratin cross-linking via lysyl oxidase and contributes to the structural integrity of nails. Copper deficiency is associated with brittle, malformed nails. This link is established through deficiency evidence and the understood role of copper in connective tissue and keratinized structures.
Copper is essential for myelination of the brain and spinal cord, neurotransmitter synthesis (via dopamine β-hydroxylase and peptidylglycine amidating monooxygenase), and synaptic transmission. Copper deficiency causes myelopathy, peripheral neuropathy, and demyelination. These effects are documented in human case series and clinical studies.
Acquired copper deficiency is a recognized cause of myelopathy and peripheral neuropathy in humans. Clinical studies document that copper deficiency produces sensory ataxia, weakness, and demyelination reversible with copper supplementation. Risk is elevated after bariatric surgery, with excessive zinc supplementation, or with malabsorption.
Copper is a trace mineral required as a cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin in bone matrix. Copper deficiency impairs collagen crosslinking, reducing bone strength, and has been associated with increased osteoporosis risk. It is listed among essential bone health minerals in comprehensive nutritional reviews.
Copper is an essential nutrient during pregnancy, required for fetal brain, heart, vascular, skeletal, and immune development. Maternal copper requirements increase during gestation. Low maternal serum copper has been associated with premature delivery and impaired fetal growth indices. Copper deficiency during embryogenesis causes gross structural and biochemical abnormalities.
Copper metabolism is demonstrably altered in rheumatoid arthritis (RA): meta-analyses show elevated serum copper in RA patients versus controls. Copper complexes have anti-inflammatory properties relevant to RA, and RA patients carry increased ceruloplasmin as an acute-phase reactant. Clinical studies on copper supplementation in RA are limited but the biochemical relationship is established.
Copper promotes dermal collagen and elastin synthesis via lysyl oxidase and GHK-Cu signaling. Clinical studies using copper oxide-embedded textiles demonstrated reduced facial wrinkle depth and improved skin elasticity with continued use. Ex vivo human skin models show copper ions increase pro-collagen 1, elastin, and TGF-β1 secretion.
Copper is an obligatory cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, providing skin its firmness and elasticity. GHK-Cu peptide stimulates fibroblast collagen synthesis. Ex vivo and clinical studies confirm copper exposure increases pro-collagen 1 and elastin in human skin.
Copper is recognized among essential trace minerals for thyroid function in peer-reviewed nutritional reviews. Cross-sectional studies show copper levels correlate with FT4 and TSH. Copper is required for the function of enzymes involved in thyroid hormone metabolism and immune regulation relevant to autoimmune thyroid disease.
Copper is indispensable for tyrosinase activity and melanin synthesis; copper deficiency directly causes hypopigmentation. Serum copper levels in vitiligo patients have been studied in multiple clinical observations, with a 2024 meta-analysis (41 studies, >13,000 subjects) confirming copper's integral role in melanogenesis disruption in vitiligo.
Copper is required for multiple wound-healing processes: it induces VEGF-driven angiogenesis, activates lysyl oxidase for collagen/elastin cross-linking, upregulates integrins, and stabilizes fibrinogen. Copper oxide wound dressings have demonstrated statistically faster wound healing vs. controls in human trials. GHK-Cu peptide promotes tissue remodeling and granulation.
Copper is an essential cofactor for lysyl oxidase, which cross-links collagen and elastin in the follicle connective tissue, and for tyrosinase involved in melanin synthesis. Copper deficiency has been associated with hair loss and premature graying. Copper peptides (GHK-Cu) have demonstrated hair growth stimulation in preclinical models.
Body systems that Copper may help support.
Go back